DOI QR코드

DOI QR Code

Correlations Between Serum IL33 and Tumor Development: a Meta-analysis

  • Chen, Xiang-Jun (Department of Medical Quality Control, West China Hospital, Sichuan University) ;
  • Huang, Ying-De (Department of Medical Quality Control, West China Hospital, Sichuan University) ;
  • Li, Nian (Department of Medical Quality Control, West China Hospital, Sichuan University) ;
  • Chen, Min (Department of Medical Quality Control, West China Hospital, Sichuan University) ;
  • Liu, Fang (Department of Medical Quality Control, West China Hospital, Sichuan University) ;
  • Pu, Dan (Clinical Skill Experiment Teaching Center, West China Hospital, Sichuan University) ;
  • Zhou, Tao-You (Department of Infectious Disease, West China Hospital, Sichuan University)
  • Published : 2014.04.30

Abstract

Background: Interleukin-33 (IL-33) has recently been implicated in tumor development. Methods: Data was obtained from PubMed, EMBASE, Clinical trial, Cochrane Library, Web of Science, CNKI and Wanfang databases. After quality assessment and data extraction, a meta-analysis was performed using Review Manager 5.2 software. Results: There were eight documents included in this meta-analysis. The results showed IL33 levels to be higher in tumor patients than that in health people, but no correlations tumor stage, metastasis and survival time of tumor patients were evident. Conclusion: IL33 may be useful as an alarm factor in tumor detection and prognosis.

Keywords

References

  1. Williams MA, Bevan MJ (2007). Effector and memory CTL differentiation, Annu Rev Immunol, 25, 171-92. https://doi.org/10.1146/annurev.immunol.25.022106.141548
  2. Schmitz J, Owyang A, Oldham E, et al (2005). IL-33, an interleukin-1-likecytokine that signals via the IL-1 receptorrelated protein ST2 and induces Thelper type 2-associated cytokines. Immunity, 23, 479–90. https://doi.org/10.1016/j.immuni.2005.09.015
  3. Sun P, Ben Q, Tu S, et al (2011). Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci, 56, 3596-601. https://doi.org/10.1007/s10620-011-1760-5
  4. Walzl G, Matthews S, Kendall S, et al (2001). Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)-but not Th1-driven immunopathology. J Exp Med, 193, 785-92. https://doi.org/10.1084/jem.193.7.785
  5. Zhang P, Liu XK, Chu Z, et al (2012). Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res, 40, 1654-61. https://doi.org/10.1177/030006051204000504
  6. Kakkar R and Lee RT (2008). The IL-33/ST2 pathway:therapeutic target and novel biomarker. Nat Rev Drug Discov, 7, 827–40. https://doi.org/10.1038/nrd2660
  7. Humphreys NE, Xu D, Hepworth MR, et al (2008). IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol, 180, 2443-9. https://doi.org/10.4049/jimmunol.180.4.2443
  8. Jovanovic IP, Pejnovic NN, Radosavljevic GD, et al (2014). Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer, 134, 1669-82. https://doi.org/10.1002/ijc.28481
  9. Jovanovic I, Radosavljevic G, Mitrovic M, et al (2011). ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immuno, l41, 1902-12. https://doi.org/10.1002/eji.201141417
  10. Liew FY, Pitman N, McInnes IB (2010). Disease-associated functions of IL-33: the new kid in the IL-1 family, Nat Rev Immunol, 10, 103-10. https://doi.org/10.1038/nri2692
  11. Lopetuso LR, Scaldaferri F, Pizarro TT (2012). Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair, 5, 18. https://doi.org/10.1186/1755-1536-5-18
  12. Naumnik W, Naumnik B, Niewiarowska K, et al (2012). Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?Exp Oncol, 34, 348-53.
  13. Oshikawa K, Yanagisawa K, Ohno S, et al (2002). Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am J Respir Crit Care Med, 165, 1005-9. https://doi.org/10.1164/ajrccm.165.7.2105109
  14. Roy A, Ganesh G, Sippola H, et al (2014). Mast Cell Chymase Degrades the Alarmins Heat Shock Protein 70, Biglycan, HMGB1, and Interleukin-33 (IL-33). and Limits Dangerinduced Inflammation. J Biol Chem, 289, 237-50. https://doi.org/10.1074/jbc.M112.435156
  15. Santulli P, Even M, Chouzenoux S, et al (2013). Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden. Hum Reprod, 28, 2126-33. https://doi.org/10.1093/humrep/det238
  16. Bourgeois E, Van LP, Samson M, et al (2009). The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol, 39, 1046–55. https://doi.org/10.1002/eji.200838575
  17. Arshad MI, Piquet-Pellorce C, Samson M (2012). IL-33 and HMGB1 alarmins: sensors of cellular death and their involvement in liver pathology. Liver Int, 32, 1200-10. https://doi.org/10.1111/j.1478-3231.2012.02802.x
  18. Bergis D, Kassis V, Ranglack A, et al (2013). High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol, 6, 311-8. https://doi.org/10.1593/tlo.12418
  19. Bonilla WV, Frohlich A, Senn K, et al (2012). The alarmin interleukin-33 drives protective antiviral CD8 (+). T cell responses. Science, 335, 984-9. https://doi.org/10.1126/science.1215418
  20. Chackerian AA, Oldham ER, Murphy EE, et al (2007). IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol, 179, 2551–5. https://doi.org/10.4049/jimmunol.179.4.2551
  21. Chen SF, Nieh S, Jao SW, et al (2013). The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol, 231, 180-9. https://doi.org/10.1002/path.4226
  22. Dobrzanski MJ, Reome JB, Hylind JC, et al (2006). CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer. J Immunol, 177, 8191-201. https://doi.org/10.4049/jimmunol.177.11.8191
  23. Gangemi S, Allegra A, Profita M, et al (2013). Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia. Cancer Invest, 31, 212-3. https://doi.org/10.3109/07357907.2013.764566
  24. Hu LA, Fu Y, Zhang DN, et al (2013). Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2563-6. https://doi.org/10.7314/APJCP.2013.14.4.2563

Cited by

  1. IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2–ERK1/2 Pathway vol.60, pp.5, 2015, https://doi.org/10.1007/s10620-014-3463-1
  2. T cells in resected hepatocellular carcinoma prolong patient survival vol.61, pp.6, 2015, https://doi.org/10.1002/hep.27728
  3. A novel isoform of IL-33 revealed by screening for transposable element promoted genes in human colorectal cancer vol.12, pp.7, 2017, https://doi.org/10.1371/journal.pone.0180659
  4. Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma vol.127, pp.3, 2017, https://doi.org/10.1080/00207454.2016.1175441
  5. An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer vol.114, pp.1, 2016, https://doi.org/10.1038/bjc.2015.433